Tafenoquine combinations show promising parasite clearance in immunocompromised patients with babesiosis
60 Degrees Pharmaceuticals reports negative Babesia PCR tests in five patients receiving tafenoquine combinations, with FDA discussions planned.
60 Degrees Pharmaceuticals reports negative Babesia PCR tests in five patients receiving tafenoquine combinations, with FDA discussions planned.
Lilac Biosciences and Soin Neuroscience map an RNA biomarker path for neuropathic pain, but clinical validation remains the decisive test.